The TRPC3-mediated profibrotic effects are linked to cardiac disease conditions such as atrial fibrillation (Harada et al., 2012; Han et al., 2020), hypertension (He et al., 2019), and pressure overload (Numaga-Tomita et al., 2016), where the disease conditions directly or indirectly upregulate the expression of TRPC3 or activate the channels. Here, TRPC3 is linked to atrial fibrillation.